Dr. Daniel Catenacci, MD, director of the Gastrointestinal Oncology Program at the University of Chicago, discusses data from Astellas’ Phase 2 FAST study, which evaluated zolbetuximab, an investigational first-in-class anti-CLDN18.2 monoclonal antibody, in combination with first-line epirubicin, oxaliplatin, and capecitabine (EOX) in patients with advanced gastric cancer. He discusses efficacy and safety results, as well as patient-reported outcomes (PROs) data from the study. He also shares background on the overall gastric cancer landscape and unmet needs of patients facing this disease.
Daniel Catenacci, MD, is an adult gastrointestinal medical oncologist and director of the Gastrointestinal Oncology Program at the University of Chicago. He serves as the assistant director of translational research in the Comprehensive Cancer Center. In addition to his clinical practice, Dr. Catenacci is an active basic and clinical researcher, focusing on the treatment of gastroesophageal (esophagus, gastroesophageal junction, and stomach) cancers. His bench-to-bedside translational research has an overarching goal to validate and improve personalized treatment, immunotherapy, and precision medicine for gastroesophageal cancer and other GI cancers.